Follistatin 344
A myostatin-linked muscle-growth name that remains popular in research-market and performance discussions despite limited conventional therapeutic development.
Also referenced as: FS344, Follistatin
Also appears in: Other
This name primarily lives in the research market and should not be read like an approved pharmaceutical product.
Primary lane: Muscle Growth. Also surfaces under Other for browsing and discovery.
FS344, Follistatin
No FDA label signal · 75 trials · 2941 PubMed results
Follistatin 344 has name-matched human trials with published or reported controlled evidence, but is not FDA-approved. The research is real and ongoing — treat findings as developing rather than settled.
Follistatin 344 has 10 name-matched clinical trials (highest phase: Phase 4) and 2941 PubMed-indexed publications and is not FDA-approved. Human trials are registered but none have posted results yet.
Re-checked nightly against the registries — tracked since 2026-07-09. No band changes yet.
Grades evidence strength, not efficacy or safety. Research-use context; not medical advice. Graded 2026-07-13 from PubMed, ClinicalTrials.gov, ISRCTN, openFDA, Health Canada, and OpenAlex — computed deterministically and refreshed nightly, with a retraction check. How we grade →
What follistatin 344 is
Follistatin 344, often shortened to FS344, is a muscle-growth-associated research-market name tied to myostatin and activin inhibition.
Why it matters
It has stayed popular for years in performance and muscle-enhancement discussions even though the formal therapeutic-development story is much thinner and more complicated than the market hype suggests.
Regulatory context
Follistatin 344 is not FDA approved as a mainstream peptide therapy. The name is most relevant in research-market, performance, and anti-doping conversations.
Practical reading note
This is one of the clearest examples of a compound that is culturally important in peptide circles even when the clean clinical-development pathway is limited.